Bupivacaine Liposome (Exparel) — CPB 0941 | AETNA Coverage Update

TL;DR: Aetna modified CPB 0941 governing bupivacaine liposome (Exparel) coverage, effective January 5, 2026. The policy draws a hard line between four covered indications and a 15-item list of experimental uses — and your billing team needs to know exactly which side of that line your claims fall on.

If you bill Exparel for anything outside the four approved indications, Aetna will deny the claim. This update codifies what counts as medically necessary and formally labels 15 specific uses as experimental or investigational. The primary covered code is CPT 64415 for interscalene brachial plexus nerve block, alongside a long list of procedure codes that map to non-covered indications.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna
Policy	Bupivacaine Liposome (Exparel) — CPB 0941
Policy Code	CPB 0941
Change Type	Modified
Effective Date	January 5, 2026
Impact Level	High
Specialties Affected	Anesthesiology, orthopedic surgery, urology, general surgery, cardiac surgery, breast reconstruction, colorectal surgery, pediatric urology
Key Action	Audit every Exparel claim against the four covered indications before submitting to Aetna

---

Aetna Bupivacaine Liposome Coverage Criteria and Medical Necessity Requirements 2026

The Aetna Exparel coverage policy under CPB 0941 covers bupivacaine liposome injectable suspension for four specific indications. Only four. Everything else is experimental by default.

Here's what meets medical necessity under this updated policy:

Notice the age cutoff. Single-dose infiltration covers patients 6 and older. The three nerve block indications are adults only. If you're billing a nerve block for a pediatric patient, Aetna won't cover it under this policy.

Ultrasound guidance doesn't affect coverage here. Aetna covers these four indications "with or without ultrasound guidance." That's a straightforward detail, but it removes one potential denial trigger.

Bupivacaine liposome billing under this coverage policy requires that the documented indication match one of these four precisely. If your operative report or anesthesia record references a different nerve block or a use case not on the approved list, you're looking at a claim denial.

---

Aetna Exparel Exclusions and Non-Covered Indications

This is where the policy gets sharp. Aetna lists 15 specific uses of bupivacaine liposome as experimental, investigational, or unproven. The clinical rationale is the same across all 15: insufficient evidence in peer-reviewed literature.

The real issue here isn't just clinical judgment — it's the breadth of what's excluded. Several of these are common surgical contexts where anesthesiologists and surgeons routinely reach for Exparel. If your facility uses Exparel in any of these settings, you have a reimbursement problem with Aetna members.

The 15 non-covered indications under CPB 0941:

A few of these deserve extra attention. TAP blocks show up twice — once for DIEP flap breast reconstruction, once for laparoscopic colorectal resections. Both are settings where Exparel is frequently used clinically. If your surgeons use Exparel for either, you're billing into a flat denial for Aetna members.

The peri-articular injection during reverse shoulder arthroplasty is another common one. Surgeons inject Exparel into the joint capsule routinely in shoulder arthroplasty. Aetna won't pay for it in this context.

Laparoscopy port instillation is also on the excluded list. This is a widespread technique — many general surgeons use Exparel at trocar sites. Under this coverage policy, it doesn't qualify.

If you're not sure how your mix of Exparel cases maps to this exclusion list, talk to your compliance officer before the January 5, 2026 effective date.

---

Coverage Indications at a Glance

---

Aetna Exparel Billing Guidelines and Action Items 2026

The billing guidelines under CPB 0941 are straightforward — but the enforcement risk is real. Here's what your billing team should do now.

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Bupivacaine Liposome Under CPB 0941

Covered CPT Codes (When Selection Criteria Are Met)

Code	Type	Description Copy
64415	CPT	Injection, anesthetic agent; brachial plexus, single

Not Covered / Experimental CPT Codes

These codes appear in the policy under non-covered indications. Billing Exparel in these contexts will result in a claim denial for Aetna members.

Note on HCPCS and ICD-10 codes: The CPB 0941 policy data does not list specific HCPCS or ICD-10-CM codes for Exparel claims. Code your underlying surgical procedures with standard ICD-10-CM diagnosis codes per your normal protocols. Do not assume diagnosis code coverage without verifying against plan-level documentation.

---